指南与共识乳腺癌放疗胸部肿瘤放疗泌尿生殖与妇科肿瘤放疗

美国癌症指南一致性诊疗及死亡率的种族差异

Racial disparities in guideline-concordant cancer care and mortality in the United States.
指南 / 共识 · Adv Radiat Oncol · 2018-05-04

该研究利用监测、流行病学和最终结果(SEER)医保数据,评估2006至2011年确诊的III期乳腺癌、I期或III期非小细胞肺癌及III期前列腺癌的黑人及非西班牙裔白人患者(年龄>65岁)接受指南一致性治愈性治疗的比例及对死亡率差异的影响。黑人患者在多个癌种中接受指南一致性治疗的比例低于白人,调整指南一致性后黑人患者全因死亡率风险比降低并更接近1.00。

要点

  • III期乳腺癌乳房切除术后放疗:黑人53% vs 白人61%(P=0.0014)。
  • I期非小细胞肺癌立体定向放疗或手术:黑人61% vs 白人75%(P<0.0001)。
  • III期前列腺癌放疗或前列腺切除术:黑人82% vs 白人95%(P<0.0001)。

核心结论

  • 多个癌种中接受治愈性癌症治疗的种族差异影响了种族死亡率差异。
  • 以指南一致性诊疗为基准可能为改善癌症治疗和生存的差异提供机会。

研究设计与样本

  • 利用监测、流行病学和最终结果(SEER)医保数据,评估2006至2011年确诊的年龄>65岁黑人及非西班牙裔白人患者。
  • 纳入III期乳腺癌(n=3607)、I期(n=14605)或III期(n=15609)非小细胞肺癌、III期前列腺癌(n=3548)患者。
  • 通过理赔数据识别化疗、手术和放射治疗(RT),基于美国国家综合癌症网络(NCCN)治愈性治疗指南使用Pearson χ2检验种族与指南一致性的关联,使用Cox比例风险模型建模死亡风险。

主要发现

  • III期乳腺癌乳房切除术后放疗:黑人53% vs 白人61%(P=0.0014)。
  • I期非小细胞肺癌立体定向放疗或手术:黑人61% vs 白人75%(P<0.0001)。
  • III期非小细胞肺癌化疗联合放疗或手术:黑人36% vs 白人41%(P=0.0001)。
  • III期前列腺癌放疗或前列腺切除术:黑人82% vs 白人95%(P<0.0001)。
  • 调整指南一致性后,显示黑人患者全因死亡率风险升高的风险比降低并更接近1.00,病因特异性死亡率观察到类似影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We identified the frequency of racial disparities in guideline-concordant cancer care for select common disease sites in the United States and the impact of guideline concordance on mortality disparities. METHODS AND MATERIALS: Using Surveillance, Epidemiology, and End Results Medicare data, we evaluated patients age >65 years of black or non-Hispanic white race who were diagnosed with stage III breast (n = 3607), stage I (n = 14,605) or III (n = 15,609) non-small cell lung, or stage III prostate (n = 3548) cancer between 2006 and 2011. Chemotherapy, surgery, and radiation therapy (RT) treatments were identified using claims data. Pearson χ2 was used to test the associations between race and guideline concordance on the basis of National Comprehensive Cancer Network curative treatment guidelines. Mortality risks were modeled using Cox proportional hazards. RESULTS: Black patients were less likely to receive guideline-concordant curative treatment than non-Hispanic white patients for stage III breast cancer postmastectomy RT (53% black, 61% white; P = .0014), stage I non-small cell lung cancer stereotactic radiation or surgery (61% black, 75% white; P < .0001), stage III non-small cell lung cancer chemotherapy in addition to RT or surgery (36% black, 41% white; P = .0001), and stage III prostate cancer RT or prostatectomy (82% black, 95% white; P < .0001). Disparities in guideline concordance impacted racial mortality disparities. Specifically, hazard ratios that demonstrated elevated all-cause mortality risks in black patients were lowered (and more closely approached hazard ratio of 1.00) after adjusting for guideline concordance. A similar impact for cause-specific mortality was observed. CONCLUSIONS: Racial disparities in the receipt of curative cancer therapy impacted racial mortality disparities across multiple cancer sites. Benchmarking adherence to guideline-concordant care could represent an opportunity to stimulate improvements in disparities in cancer treatment and survival.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Fang P, He W, Gomez D, et al. Racial disparities in guideline-concordant cancer care and mortality in the United States. Adv Radiat Oncol. 2018. PMID: 30202793. doi:10.1016/j.adro.2018.04.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。